(Q38067828)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23244671%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

title

Pancreatic cancer - cost for overtreatment with gemcitabine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23244671%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23244671%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Daniel Ansari

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23244671%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Roland Andersson

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23244671%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

17 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23244671%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23244671%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

52

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23244671%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

1146-1151

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23244671%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23244671%20AND%20SRC:MED&resulttype=core&format=json

Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry

20 February 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.744140

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.744140

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.744140

Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.744140

Recent molecular advances in studies of the concentrative Na+-dependent nucleoside transporter (CNT) family: identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosi

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.744140

Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.744140

Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.744140

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.744140

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.744140

Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.744140

The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.744140

Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.744140

Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.744140

In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.744140

Long-term follow-up and cost analysis following surgery for small bowel obstruction caused by intra-abdominal adhesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.744140

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.744140

Pancreatic cancer, healthcare cost, and loss of productivity: a register-based approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.744140

Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.744140

Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F0284186X.2012.744140